Update on hormone-refractory prostate cancer
Authors:
- Nancy A DawsonNDNancy A Dawson
- 1 May 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Urology
- Vol. 14 (3) , 185-193
Abstract
Androgen deprivation therapy is the cornerstone treatment for men with de novo or recurrent metastatic prostate cancer. Unfortunately, androgen deprivation therapy is primarily palliative, with nearly all men progressing to an androgen-independent state. Hormone-refractory prostate cancer presents significant management challenges and is the focus of this review. Investigations into the pathophysiology of hormone-refractory prostate cancer, the exploration of chemotherapeutic combinations, novel biological targets, skeletal protectants, and radiopharmaceuticals, as well as new prognostic tools are expanding the clinician's armamentarium and improving patient outcomes. Bisphosphonates and chemotherapy are providing effective palliative approaches. Phase II trials of taxane-based regimens show higher response rates and longer survival than has typically been achieved with existing standards. Two completed randomized phase III studies to be reported in mid-2004 will more definitively answer the question of whether currently available chemotherapy can improve survival.Keywords
This publication has 63 references indexed in Scilit:
- Androgen Receptor Mutations in Androgen-Independent Prostate Cancer: Cancer and Leukemia Group B Study 9663Journal of Clinical Oncology, 2003
- Androgen receptor involvement in the progression of prostate cancer.Endocrine-Related Cancer, 2003
- Cancer Statistics, 2003CA: A Cancer Journal for Clinicians, 2003
- Androgen Receptor (AR) Coregulators: An OverviewEndocrine Reviews, 2002
- Phase II Study of Docetaxel, Estramustine, and Low-Dose Hydrocortisone in Men With Hormone-Refractory Prostate Cancer: A Final Report of CALGB 9780Journal of Clinical Oncology, 2001
- Prostate Cancer: Screening and Early DetectionCancer Control, 2001
- HIGH DOSE BICALUTAMIDE FOR ANDROGEN INDEPENDENT PROSTATE CANCER: EFFECT OF PRIOR HORMONAL THERAPYJournal of Urology, 1998
- Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.Journal of Clinical Oncology, 1997
- Dehydroepiandrosterone Activates Mutant Androgen Receptors Expressed in the Androgen-Dependent Human Prostate Cancer Xenograft CWR22 and LNCaP CellsMolecular Endocrinology, 1997
- In vivo amplification of the androgen receptor gene and progression of human prostate cancerNature Genetics, 1995